TABLE 3.
Summary of the Most Frequency Occurring Adverse Experiences by Treatment Group
| Adverse Experience | Treatment Group
|
||
|---|---|---|---|
| Selfotel | Placebo | p* | |
| Agitation | 101 (36) | 39 (1) | 0.001 |
| Hallucination | 59 (21) | 13 (5) | 0.001 |
| Fever | 52 (19) | 53 (19) | |
| Hypertension | 47 (17) | 28 (10) | 0.015 |
| Confusion | 46 (16) | 16 (6) | 0.001 |
| Constipation | 37 (13) | 55 (19) | 0.052 |
| Headache | 35 (13) | 55 (19) | |
| Somnolence | 30 (11) | 29 (10) | |
| Cerebrovascular disorder | 29 (10) | 13 (5) | 0.009 |
| Urinary tract infection | 29 (10) | 36 (13) | |
| Vomiting | 19 (7) | 30 (11) | |
| Coma | 15 (5.3) | 7 (2.4) | 0.075 |
| Stupor | 12 (4.3) | 0 | 0.001 |
*
Adverse experiences were reported by >10% of patients treated with Selfotel or placebo; by univariate analysis.24
Values are number of patients (%) with adverse experiences.
From Davis et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 31:347–354. Copyright © 2000, Lippincott Williams and Wilkins. All rights reserved.